- Call us: +91 97377 01204 | +91 95107 05371
- Email: info@surgicarepharma.com
- 24/7 hrs Open
Dapagliflozin 10 mg, Sitagliptin 100 mg, and Metformin Hydrochloride (Extended-Release) 1000 mg Tablets are an oral, fixed-dose combination used to manage type 2 diabetes mellitus in adults. This triple therapy combines three agents with complementary mechanisms. Dapagliflozin, an SGLT2 inhibitor, lowers blood glucose by promoting urinary glucose excretion. Sitagliptin, a DPP-4 inhibitor, enhances glucose-dependent insulin secretion and reduces glucagon levels. Metformin (ER), a biguanide, decreases hepatic glucose production and improves insulin sensitivity.
Sitagliptin and Metformin Hydrochloride Tablets are a combination oral antidiabetic medication used to manage type 2 diabetes mellitus in adults. Sitagliptin is a DPP-4 inhibitor that increases incretin hormone levels, enhancing glucose-dependent insulin secretion and reducing glucagon production, leading to better blood sugar control. Metformin, a biguanide, works by reducing hepatic glucose production, improving insulin sensitivity, and decreasing intestinal glucose absorption. Together, they help control both fasting and postprandial blood glucose levels.